Literature DB >> 16300868

Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons.

K L Nichol1, J Nordin, J Mullooly.   

Abstract

Studies assessing the clinical and economic benefits of vaccination in the elderly have used different clinical outcomes (e.g. hospitalizations for pneumonia or influenza versus hospitalizations for respiratory and cardiovascular causes) and different outcome periods (e.g. peak versus total influenza season) on which to base estimates of clinical effectiveness and cost effectiveness. We explored the implications of these varying approaches by comparing two health economic analysis models of influenza vaccination of community-dwelling elderly persons. We developed computerized models using clinical data from 3 large US HMOs for the 1998-1999 and 1999-2000 influenza seasons. The primary health economic model used a broad definition of clinical events and outcome period and included hospitalizations for all respiratory and cardiovascular events that occurred during the entire influenza season. The alternative model used more restrictive definitions and included pneumonia or influenza hospitalizations occurring during the peak influenza season. The results of Monte Carlo simulation showed that, with the more inclusive primary model, influenza vaccination resulted in net medical care cost savings due to fewer respiratory or cardiovascular hospitalizations of Dollars 71/person vaccinated (5th-95th percentile Dollars 32-118) and net savings of Dollars 809/year of life saved (5th-95th percentile Dollars 331-1450). In contrast, the alternate model found costs of Dollars 3.50/person vaccinated (5th-95th percentile Dollars -11 to 5) and net costs of Dollars 91/year of life saved (5th-95th percentile Dollars -309 to 126). Our findings confirm that influenza vaccination of the elderly is most likely cost saving and supports policies and programs that advocate routine immunization of all persons 65 and older. They also highlight how different outcome definitions can influence the results of health economic analyses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16300868     DOI: 10.1016/j.vaccine.2005.10.004

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Estimating the Effect of Influenza Vaccination on Nursing Home Residents' Morbidity and Mortality.

Authors:  Aurora Pop-Vicas; Momotazur Rahman; Pedro L Gozalo; Stefan Gravenstein; Vincent Mor
Journal:  J Am Geriatr Soc       Date:  2015-08-17       Impact factor: 5.562

2.  Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: a randomized study in US adults.

Authors:  James D Campbell; Christopher V Chambers; Rebecca C Brady; Michael C Caldwell; Nathan L Bennett; Marc A Fourneau; Varsha K Jain; Bruce L Innis
Journal:  Hum Vaccin       Date:  2011-01-01

3.  Does influenza vaccination of older adult Medicare beneficiaries lower treatment costs for acute and chronic respiratory disease?

Authors:  Bruce Stuart; Amy Davidoff; Jennifer Lloyd; Thomas Shaffer; J Samantha Shoemaker; Jason Kemner
Journal:  Am J Geriatr Pharmacother       Date:  2010-06

4.  Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults.

Authors:  Xu Yao; Robert G Hamilton; Nan-ping Weng; Qian-Li Xue; Jay H Bream; Huifen Li; Jing Tian; Shu-Hui Yeh; Barbara Resnick; Xiyan Xu; Jeremy Walston; Linda P Fried; Sean X Leng
Journal:  Vaccine       Date:  2011-05-10       Impact factor: 3.641

Review 5.  Interventions to increase influenza vaccination rates of those 60 years and older in the community.

Authors:  Roger E Thomas; Diane L Lorenzetti
Journal:  Cochrane Database Syst Rev       Date:  2014-07-07

Review 6.  Interventions to increase influenza vaccination rates of those 60 years and older in the community.

Authors:  Roger E Thomas; Diane L Lorenzetti
Journal:  Cochrane Database Syst Rev       Date:  2018-05-30

7.  Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons.

Authors:  Patricia R Blank; Matthias Schwenkglenks; Thomas D Szucs
Journal:  BMC Public Health       Date:  2008-08-01       Impact factor: 3.295

Review 8.  Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients.

Authors:  Arnt-Ove Hovden; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

9.  Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy.

Authors:  Marco Villa; Steven Black; Nicola Groth; Kenneth J Rothman; Giovanni Apolone; Noel S Weiss; Ivana Aquino; Liana Boldori; Fausta Caramaschi; Antonio Gattinoni; Giancarlo Malchiodi; Antonio Crucitti; Giovanni Della Cioppa; Elio Scarpini; Domenico Mavilio; Salvatore Mannino
Journal:  Am J Epidemiol       Date:  2013-07-17       Impact factor: 4.897

Review 10.  What is the role of virus vaccination in patients with asthma?

Authors:  Herman J Bueving; Johannes C van der Wouden
Journal:  Curr Allergy Asthma Rep       Date:  2007-04       Impact factor: 4.806

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.